Trial Profile
A Phase II study to evaluate the efficacy and safety of PTK787 [vatalanib] in patients with metastatic cutaneous melanoma [malignant melanoma]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vatalanib (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms PTK787
- 26 Mar 2009 Bayer Schering Pharma added as trial sponsor as reported by United Kingdom Clinical Research Network.
- 26 Mar 2009 New source identified and integrated (United Kingdom Clinical Research Network).
- 04 May 2008 Status changed from recruiting to in progress according to clinicaltrials.gov record.